Rosuvastatin (Crestor): Adjunct For Slowing Atherosclerosis

p433crestor

Rosuvastatin calcium (Crestor, Astra-Zeneca) has been approved as an adjunct to diet to delay the progression of atherosclerosis in patients with elevated cholesterol levels.

In the Measuring Effects on intima media Thickness: an Evaluation Of Rosu-vastatin (METEOR) study, researchers evaluated the effects of this drug on plaque build-up in the arteries. The new label conforms to the FDA’s revised format designed to draw physicians’ attention to important drug information in an effort to reduce errors.

Rosuvastatin is indicated as adjunctive therapy to diet to reduce elevated total cholesterol, LDL-cholesterol, ApoB, nonHDL-cholesterol, and triglycerides and to increase HDL-cholesterol in adults with primary hyperlipidemia or mixed dyslipidemia. It is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adults as part of a treatment strategy to lower total and LDL cholesterol to target levels.

For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of rosuvastatin is 10 mg. The 40-mg dose is reserved for those who have not achieved their LDL-C goal with 20 mg once daily.

When patients are beginning statin therapy or switching from another statin, the appropriate starting dose for rosuvastatin should be used first. After that, the dose should be titrated according to the patient’s individual goal of therapy.

(Source: AstraZeneca, November 9, 2007.)